SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Passive Stake in Mustang Bio

Armistice Capital, LLC and Steven Boyd have disclosed a passive beneficial ownership of 5,106,287 shares, representing 9.99% of Mustang Bio, Inc.'s common stock as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership of Mustang Bio, Inc. common stock.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 5,106,287 shares of Mustang Bio, Inc. common stock.
• This ownership represents 9.99% of the total class of securities outstanding.
• The Reporting Persons hold shared voting power and shared dispositive power over all 5,106,287 shares.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is deemed to beneficially own the securities held by the Master Fund.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual regulatory filing disclosing beneficial ownership and does not contain information that would typically convey positive or negative sentiment about the issuer's performance or outlook.

Industry Context

This filing is a standard regulatory disclosure by an investment firm, Armistice Capital, and its managing member, Steven Boyd, indicating a significant passive stake in Mustang Bio, Inc., a biotechnology company. Such disclosures provide transparency regarding major shareholders in publicly traded companies.

Key Dates

Keywords

Mustang Bio, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, passive investment, equity stake, SEC filing